<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9"
        xmlns:news="http://www.google.com/schemas/sitemap-news/0.9">
  <url>
    <loc>https://allsci.com/news/grants/zelpultide-alfa-airway-therapeutics-receives-19/</loc>
    <news:news>
      <news:publication><news:name>AllSci</news:name><news:language>en</news:language></news:publication>
      <news:publication_date>2026-09-18T17:30:11.072007Z</news:publication_date>
      <news:title>Airway Therapeutics gets NHLBI grant for zelpultide alfa BPD trial</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://allsci.com/news/clinical-trials/heavy-menstrual-bleeding-hemab-doses-first/</loc>
    <news:news>
      <news:publication><news:name>AllSci</news:name><news:language>en</news:language></news:publication>
      <news:publication_date>2026-09-18T17:21:48.181069Z</news:publication_date>
      <news:title>Hemab doses first volunteer in Phase I trial of HMB-003 for heavy menstrual bleeding</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://allsci.com/news/tecvayli-chmp-opinion-recommends-johnson-johnsons/</loc>
    <news:news>
      <news:publication><news:name>AllSci</news:name><news:language>en</news:language></news:publication>
      <news:publication_date>2026-09-18T16:46:33.458469Z</news:publication_date>
      <news:title>CHMP&apos;s September meeting highlights</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://allsci.com/news/tecvayli-multiple-myeloma-chmp-recommends-johnson/</loc>
    <news:news>
      <news:publication><news:name>AllSci</news:name><news:language>en</news:language></news:publication>
      <news:publication_date>2026-09-18T16:45:09.549622Z</news:publication_date>
      <news:title>CHMP backs J&amp;J’s Tecvayli monotherapy after one prior myeloma therapy</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://allsci.com/news/regulatory-setbacks-safety/kalydeco-eu-application-vertex-withdraws-for/</loc>
    <news:news>
      <news:publication><news:name>AllSci</news:name><news:language>en</news:language></news:publication>
      <news:publication_date>2026-09-18T16:33:05.134614Z</news:publication_date>
      <news:title>Vertex withdraws EU filings to expand Kaftrio/Kalydeco to younger children</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://allsci.com/news/clinical-trials/orum-aml-program-bms-ends-orums-extinguishing-usd/</loc>
    <news:news>
      <news:publication><news:name>AllSci</news:name><news:language>en</news:language></news:publication>
      <news:publication_date>2026-09-18T15:29:28.685126Z</news:publication_date>
      <news:title>BMS ends Orum’s AML program, extinguishing USD 80m in remaining milestone obligations</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://allsci.com/news/approvals/sanfilippo-syndrome-treatment-ultragenyx-secures/</loc>
    <news:news>
      <news:publication><news:name>AllSci</news:name><news:language>en</news:language></news:publication>
      <news:publication_date>2026-09-18T13:33:45.863682Z</news:publication_date>
      <news:title>Ultragenyx secures FDA approval for first treatment of Sanfilippo syndrome type A</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://allsci.com/news/research/ai-drug-discovery-stanfords-virtual-biotech-links/</loc>
    <news:news>
      <news:publication><news:name>AllSci</news:name><news:language>en</news:language></news:publication>
      <news:publication_date>2026-09-18T13:04:57.480363Z</news:publication_date>
      <news:title>Stanford Virtual Biotech links target expression patterns to higher drug success</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://allsci.com/news/approvals/pediatric-spasticity-merz-therapeutics-expands/</loc>
    <news:news>
      <news:publication><news:name>AllSci</news:name><news:language>en</news:language></news:publication>
      <news:publication_date>2026-09-18T11:45:18.155158Z</news:publication_date>
      <news:title>Merz Therapeutics expands Xeomin’s EU/EEA label to pediatric lower limb spasticity in cerebral palsy</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://allsci.com/news/clinical-trials/ava6103-phase-i-trial-avactas-achieves-clinical/</loc>
    <news:news>
      <news:publication><news:name>AllSci</news:name><news:language>en</news:language></news:publication>
      <news:publication_date>2026-09-18T11:24:21.365967Z</news:publication_date>
      <news:title>Avacta’s FAP-activated exatecan PDC shows early clinical proof of mechanism</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://allsci.com/news/licensing-and-partnerships/wuxitecan-2-license-xdc-grants-ona-exclusive/</loc>
    <news:news>
      <news:publication><news:name>AllSci</news:name><news:language>en</news:language></news:publication>
      <news:publication_date>2026-09-18T11:05:46.706749Z</news:publication_date>
      <news:title>WuXi XDC grants Ona exclusive global license to WuXiTecan-2 for single ADC</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://allsci.com/news/licensing-and-partnerships/dualitas-roche-deal-lands-usd-365m-upfront-in/</loc>
    <news:news>
      <news:publication><news:name>AllSci</news:name><news:language>en</news:language></news:publication>
      <news:publication_date>2026-09-18T11:01:04.417522Z</news:publication_date>
      <news:title>Dualitas lands USD 36.5m upfront in Roche bispecific discovery deal worth up to USD 1b</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://allsci.com/news/research/prime-assembly-boston-childrens-hospital-and/</loc>
    <news:news>
      <news:publication><news:name>AllSci</news:name><news:language>en</news:language></news:publication>
      <news:publication_date>2026-09-18T10:57:10.710555Z</news:publication_date>
      <news:title>Boston Children’s-led team develops prime assembly for large DNA insertions</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://allsci.com/news/pipe-financing/lisata-acquisition-pivots-from-oncology-to/</loc>
    <news:news>
      <news:publication><news:name>AllSci</news:name><news:language>en</news:language></news:publication>
      <news:publication_date>2026-09-18T09:28:21.327876Z</news:publication_date>
      <news:title>Lisata pivots from oncology to metabolic disease with Marea acquisition and USD 225m financing</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://allsci.com/news/pipe-financing/aethlon-medical-merger-agrees-to-with-north/</loc>
    <news:news>
      <news:publication><news:name>AllSci</news:name><news:language>en</news:language></news:publication>
      <news:publication_date>2026-09-17T17:23:30.834104Z</news:publication_date>
      <news:title>North Immunology to go public via Aethlon reverse merger backed by USD 180m PIPE</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://allsci.com/news/venture-financing/matisse-pharmaceuticals-secures-eur-14m-series-to/</loc>
    <news:news>
      <news:publication><news:name>AllSci</news:name><news:language>en</news:language></news:publication>
      <news:publication_date>2026-09-17T15:50:29.605494Z</news:publication_date>
      <news:title>Matisse secures EUR 14m Series A to advance isupartob sodium into Phase II sepsis trial</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://allsci.com/news/licensing-and-partnerships/novo-nordisk-deal-orbis-secures-up-to-usd-14b-for/</loc>
    <news:news>
      <news:publication><news:name>AllSci</news:name><news:language>en</news:language></news:publication>
      <news:publication_date>2026-09-17T15:41:51.824725Z</news:publication_date>
      <news:title>Novo signs up for Orbis macrocycle platform in USD 1.4b deal</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://allsci.com/news/clinical-trials/als-clinical-trial-acelot-begins-first-in-human/</loc>
    <news:news>
      <news:publication><news:name>AllSci</news:name><news:language>en</news:language></news:publication>
      <news:publication_date>2026-09-17T14:44:33.881998Z</news:publication_date>
      <news:title>Acelot takes TDP-43 ALS drug ACE-2223 into first-in-human trial</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://allsci.com/news/approvals/kerendia-approval-fda-expands-bayers-to-type-1/</loc>
    <news:news>
      <news:publication><news:name>AllSci</news:name><news:language>en</news:language></news:publication>
      <news:publication_date>2026-09-17T14:25:35.996784Z</news:publication_date>
      <news:title>FDA expands Bayer’s Kerendia to type 1 diabetes-associated chronic kidney disease</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://allsci.com/news/venture-financing/thyroid-eye-disease-sling-secures-usd-123m-to/</loc>
    <news:news>
      <news:publication><news:name>AllSci</news:name><news:language>en</news:language></news:publication>
      <news:publication_date>2026-09-17T13:54:06.326894Z</news:publication_date>
      <news:title>Sling secures USD 123m to advance oral TED drug linsitinib</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://allsci.com/news/grants/male-contraceptive-weill-cornell-receives-207/</loc>
    <news:news>
      <news:publication><news:name>AllSci</news:name><news:language>en</news:language></news:publication>
      <news:publication_date>2026-09-17T12:32:53.979312Z</news:publication_date>
      <news:title>Weill Cornell wins USD 2.1m NIH grant to advance on-demand male contraceptive into Phase I</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://allsci.com/news/clinical-trials/lunsumio-approval-roches-celestimo-win-supports/</loc>
    <news:news>
      <news:publication><news:name>AllSci</news:name><news:language>en</news:language></news:publication>
      <news:publication_date>2026-09-17T11:02:56.600146Z</news:publication_date>
      <news:title>Roche’s Lunsumio combination hits Phase III PFS goal in 2L+ follicular lymphoma</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://allsci.com/news/licensing-and-partnerships/parkinsons-drug-sk-biopharmaceuticals-licenses/</loc>
    <news:news>
      <news:publication><news:name>AllSci</news:name><news:language>en</news:language></news:publication>
      <news:publication_date>2026-09-17T10:41:15.603137Z</news:publication_date>
      <news:title>SK Bio licenses Parkinson’s candidate 1ST-104 in USD 314.8m deal</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://allsci.com/news/first-in-human-trials/ak158d1-clearance-akesos-receives-nmpa-phase-i/</loc>
    <news:news>
      <news:publication><news:name>AllSci</news:name><news:language>en</news:language></news:publication>
      <news:publication_date>2026-09-17T10:19:38.996775Z</news:publication_date>
      <news:title>Akeso’s EGFR/TROP2 bispecific ADC cleared for Phase I testing in China</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://allsci.com/news/research/lung-cancer-immune-evasion-penn-preclinical-study/</loc>
    <news:news>
      <news:publication><news:name>AllSci</news:name><news:language>en</news:language></news:publication>
      <news:publication_date>2026-09-17T09:37:48.506795Z</news:publication_date>
      <news:title>UPenn study identifies NSD2–SETD2–EZH2 axis in KRAS lung cancer immunity</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://allsci.com/news/licensing-and-partnerships/bispecific-adc-escugen-and-sovran-expand/</loc>
    <news:news>
      <news:publication><news:name>AllSci</news:name><news:language>en</news:language></news:publication>
      <news:publication_date>2026-09-17T09:02:41.632736Z</news:publication_date>
      <news:title>Escugen, Sovran pivot into co-development of pan-tumor bispecific MICA/B ADC</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://allsci.com/news/licensing-and-partnerships/ai-drug-discovery-novo-expands-push-with/</loc>
    <news:news>
      <news:publication><news:name>AllSci</news:name><news:language>en</news:language></news:publication>
      <news:publication_date>2026-09-17T08:49:59.498009Z</news:publication_date>
      <news:title>Novo expands AI drug discovery push with Anthropic’s Claude Science collaboration</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://allsci.com/news/venture-financing/circle-pharma-raises-usd-925m-to-advance-cid-165/</loc>
    <news:news>
      <news:publication><news:name>AllSci</news:name><news:language>en</news:language></news:publication>
      <news:publication_date>2026-09-16T18:23:12.873332Z</news:publication_date>
      <news:title>Circle Pharma raises USD 92.5m in Series E for cyclin D inhibitor</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://allsci.com/news/research/human-cortical-organoids-stanford-researchers/</loc>
    <news:news>
      <news:publication><news:name>AllSci</news:name><news:language>en</news:language></news:publication>
      <news:publication_date>2026-09-16T18:19:08.521694Z</news:publication_date>
      <news:title>Stanford builds mice with human cortical tissue to model brain development</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://allsci.com/news/clinical-trials/sky-0515-huntingtons-disease-skyhawks-posts/</loc>
    <news:news>
      <news:publication><news:name>AllSci</news:name><news:language>en</news:language></news:publication>
      <news:publication_date>2026-09-16T17:59:25.873144Z</news:publication_date>
      <news:title>Skyhawk’s SKY-0515 shows 1.59-point cUHDRS advantage at 15 months in Huntington’s disease</news:title>
    </news:news>
  </url>
</urlset>